+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years - 75Years
All Genders
ID04592640

Treatment With Human Amniotic-Derived Mesenchymal Stem Cells for Adults With Calciphylaxis and Chronic Kidney Disease Open-Label Early Phase 1 Study Evaluating Safety and Effectiveness

Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2026-03-04

9

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial focuses on patients with calciphylaxis, a rare and severe condition characterized by extremely painful skin lesions caused by reduced blood flow. The disease often leads to serious infections and has a high death rate, especially among dialysis patients. Researchers are studying whether treatment with human amniotic-derived mesenchymal stem cells hAMSCs can help these patients by addressing wound healing and related complications. Participants receive hAMSC therapy through two methods intravenous infusion and local injection. The infusion involves doses of 1.0 x 106 cells per kilogram, given three times in the first month and then once every four weeks for a total of eight doses over six months. Local injections are administered to the wound area concurrently, with a dose of 2.0 x 104 cells per square centimeter. Treatment duration may be adjusted based on each patients condition. Throughout the study, participants will be monitored for wound healing, pain levels, quality of life, infection, and survival for up to one year. The research includes regular assessments to track these outcomes and ensure safety. This study aims to better understand how hAMSC therapy affects calciphylaxis and its symptoms over time.

CONDITIONS

Brief Title

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

Research Team

N

Ningning Wang, Professor

L

Lianju Qin, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here